The capability of tumour cells to escape from therapy-induced senescence, as well as cell-non-autonomous functions of senescence, support the premise that senescence could serve as one pathway to tumour dormancy (among others that include quiescence and diapause) that is permissive for disease recurrence. Consequently, the pharmacologic targeting of senescent tumour cells could mitigate the risk for cancer resurgence, thereby enhancing the therapeutic efficacy of cancer chemotherapy.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $4.96 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Saleh T, Bloukh S, Carpenter VJ, Alwohoush E, Bakeer J, Darwish S, et al. Therapy-induced senescence: an “old” friend becomes the enemy. Cancers. 2020;12:822.
Wang B, Demaria M. The quest to define and target cellular senescence in cancer. Cancer Res. 2021;81:6087–9.
Zampetidis CP, Galanos P, Papantonis A, Zhu Y, Polyzou A, Karamitros T, et al. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. Mol Cell. 2021;81:4907–23.
Dirac AMG, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem. 2003;278:11731–4.
Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021;11:candisc.1375.2020.
Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020;1:672–80.
Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol. 2021;4:1–12.
Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, et al. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019;4:e124716.
Milanovic M, Fan DNY, Belenki D, Däbritz JH, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96–100.
Li Y, Kračun D, Dustin CM, El Massry M, Yuan S, Goossen CJ, et al. Forestalling age-impaired angiogenesis and blood flow by targeting NOX: interplay of NOX1, IL-6, and SASP in propagating cell senescence. Proc Natl Acad Sci USA. 2021;118:e2015666118.
Aguirre-Ghiso JA. Translating the science of cancer dormancy to the clinic. Cancer Res. 2021;81:4673–5.
Saleh T, Carpenter V, Tyutyunyk‐Massey L, Murray G, Leverson JD, Souers AJ, et al. Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X L ‐BAX Interaction. Mol Oncol. 2020;14:1–16.
Carpenter VJ, Saleh T, Gewirtz DA. Senolytics for cancer therapy: is all that glitters really gold? Cancers. 2021;13:723.
Research support relating to chemotherapy-induced senescence and senolytics in the Gewirtz laboratory is provided by the NIH/NCI through Grants CA 260819 and CA 239706.
The authors declare no competing interests.
Ethics approval and consent to participate
Consent to publish
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Saleh, T., Gewirtz, D.A. Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence. Br J Cancer 126, 1363–1365 (2022). https://doi.org/10.1038/s41416-022-01787-6